While testing volume will not return immediately and elevated supply costs will continue to show in H2, the underlying trajectory looks solid. Demand from customers increased and Boule continued to expand its order book in the quarter. It is also now entering Q3 at unusually high levels. The US posted another strong quarter but parts of Asia are also indicating a strong return, showing evidence of normalcy on a regional basis. Vaccination rates and spread of mutated variants will be important to follow to ramp up confidence in a broader market comeback.
’22-23e EBIT up by 4%, ‘22e EV/EBIT 13.2x
Following today’s report, we assume continued near-term gross margin headwind and lower our ‘21EBIT with 19%. Underlying, we make minor positive revisions to our instrument and consumables assumption yielding 3-4% positive EBIT revisions for ’22-23e. Boule currently trades at ‘22e EVEBIT of 13.2x, 21% below its historical average.
Aktuellt
SENASTE
